Rare lephants
Screener

Ensysce Biosciences, Inc.

ENSC ·Healthcare, Drug Manufacturers - General, United States
Analysis › Moat Score

Moat Score — Ensysce Biosciences, Inc.

Total Moat Score 5 / 30
Moat Factor Score Analysis
Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. 3 / 5 Proprietary TAAP and MPAR prodrug platforms are protected by multiple patent families (expiring 2028-2042) and PF614-MPAR holds FDA Breakthrough Therapy designation, giving real, differentiated IP even though no product is yet approved.
Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. 0 / 5 Pre-commercial and pre-revenue, with drug substance made by third-party CMOs; there is no manufacturing scale or cost structure to compare against competitors.
Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. 0 / 5 With no approved, marketed product, Ensysce has no customers to price to and thus no demonstrated pricing power.
Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. 0 / 5 Pharmaceutical prodrug development exhibits no network effects between users or prescribers.
Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. 1 / 5 Once (if) approved, prescriber habit and DEA/formulary placement could create modest switching costs, but this is speculative since no product has reached the market yet.
Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. 1 / 5 High regulatory barriers (DEA registration for controlled substances, NDA fees exceeding $4.6 million, lengthy trials) make market entry hard for new competitors, which could favor an approved first-mover like Ensysce, but this benefit is unrealized until approval.